Table 2 Main baseline demographics and clinical characteristics of patients

Age(y)

69 (64, 75)

PSA (ng/ml)

 T-PSA

35.39 (14.2, 70)

 F-PSA

4.32 (1.53, 9.00)

 F/T-PSA

0.11 (0.07, 0.17)

PI-RADS scores (n%)

 3

7 (4.32%)

 4

35 (21.60%)

 5

120 (74.07%)

T staging (n%)

 T2

42 (25.93%)

 T3a

21 (12.96%)

 T3b

49 (30.25%)

 T4

50 (30.86%)

N staging (n%)

 X

52 (32.10%)

 0

18 (11.11%)

 1

92 (56.79%)

M staging (n%)

 X

56 (34.57%)

 0

63 (38.89%)

 1a

3 (1.85%)

 1b

40 (24.69%)

Gleason score (n%)

 3 + 3

10 (6.17%)

 3 + 4

10 (6.17%)

 3 + 5

6 (3.70%)

 4 + 3

24 (14.81%)

 4 + 4

25 (15.43%)

 4 + 5

61 (37.65%)

 5 + 4

23 (14.20%)

 5 + 5

3 (1.85%)